Dwight Moxie - 15 Mar 2022 Form 4 Insider Report for Revance Therapeutics, Inc.

Signature
/s/ Terri McDowell, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Mar 2022
Net transactions value
-$80,687
Form type
4
Filing time
17 Mar 2022, 17:52:41 UTC
Previous filing
04 Feb 2022
Next filing
16 Sep 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability $45,491 -2,881 -6% $15.79 44,923 15 Mar 2022 Direct F1
transaction RVNC Common Stock Tax liability $35,196 -2,229 -5% $15.79 42,694 15 Mar 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 25,000 shares. The RSA vests in three equal annual installments from March 15, 2020, subject to Mr. Moxie's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date.
F2 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSA for 19,346 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Moxie's Continuous Service (as defined in the Plan) on each vesting date.